Farrukh T Awan

25PUBLICATIONS
116CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 07, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

|May 27, 2026
CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial.

|May 05, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

|Mar 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Richard R Furman, William G Wierda, Piers Em Patten

|Mar 09, 2026
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Somedeb Ball, Farrukh T Awan, Ben K Tomlinson

|Aug 14, 2025
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy

Pageof 5

Frequent Collaborators

4 joint publications

Alex Herrera

4 joint publications

Mazyar Shadman

3 joint publications

Mehdi Hamadani

3 joint publications

Mohamed A Kharfan-Dabaja